NEW DATA ON THE EFFECTS OF COVID-19 VACCINATION IN PATIENTS ON DIALYSIS

Two studies—from France and the United States—provide insights.

Highlights

- Results from a study from France suggest that both individual and herd vaccine-induced immunity protect against severe forms of COVID-19 in patients on dialysis.
- A U.S. study found that antibody responses following COVID-19 vaccination wane over time across vaccine types in patients on dialysis.

Washington, DC (February 10, 2022) — Two studies in CJASN offer a better understanding of the effects of COVID-19 vaccination on individuals with kidney failure who are undergoing long-term dialysis.

One study compared trends in COVID-19 hospitalizations between patients on dialysis and the general population throughout different waves of the pandemic. The study used nationwide registry data in France that included 53,365 patients on dialysis and analyzed 3,620 COVID-19–related hospitalizations in such patients. Investigators used three analytic models incorporating data on previous COVID-19 hospitalizations to predict subsequent COVID-19 hospitalizations at different time points.

During the first wave of the pandemic, COVID-19–related hospitalization rates in patients on dialysis were approximately proportional to the general population. However, during the second wave, there was a lower relative incidence for patients on dialysis patients, suggesting an effect of prevention measures in dialysis facilities. Moreover, from the beginning of the vaccination rollout, COVID-19–related hospitalization rates in patients on dialysis were lower than predictions based on the first and second waves. Adding vaccination coverages in dialysis and non-dialysis patients to equations revealed that both vaccination of dialysis patients and the general population was associated with a lower risk of COVID-19–related hospitalization in patients on dialysis.

ASN Contacts:
Christine Feheley (202) 640-4638 | cfeheley@ASN-online.org
Tracy Hampton thampton@nasw.org
“Our findings suggest that both individual and herd vaccine-induced immunity may yield a protective effect against severe forms of COVID-19 in dialysis patients,” said lead author Khalil El Karoui, MD, PhD, of the APHP Henri Mondor Hospital, in France.

Another study in CJASN focused on the antibody responses to COVID-19 vaccinations over time in 1,870 U.S. patients treated at Dialysis Clinic, Inc. who received a complete COVID-19 vaccine series and had their post-vaccine antibody titers measured as part of routine monthly blood work. Overall, 84% had not previously had COVID-19, and of these, 50% were vaccinated with the Moderna mRNA vaccine, 28% with the Pfizer/BioNTech mRNA vaccine, and 22% with the Janssen adenovirus vector vaccine.

Following vaccination, patients without prior COVID-19 had declining anti–SARS-CoV-2 antibody levels over time, and patients who had received the adenovirus vector vaccine had lower levels than those who had received an mRNA vaccine over all time periods.

“The decline in antibodies was noted as early as two months after vaccination, and levels were undetectable in about half of patients at six months after vaccination,” said lead author Caroline Hsu, MD, of Tufts Medical Center. “We therefore strongly advocate for a standardized approach of providing additional vaccine doses to all patients receiving maintenance dialysis, particularly with the rise of the omicron variant. Furthermore, there may be an important role for serial monitoring of antibody levels, with re-dosing of vaccine when the antibody response has waned.”

Dr. Hsu and her colleagues also found that patients with a strong antibody response in the first two months after full vaccination tended to have a more durable response over time. In the smaller cohort of patients with prior COVID-19, there appeared to be a more durable response.

An accompanying editorial discusses the results of these two studies and notes that “as we continue to learn about the effects of COVID-19 on the dialysis population and the ‘real-world’ effectiveness of different mitigation strategies, we must continue to adapt our approach to protect this vulnerable population as best as possible.”

Dr. El Karoui’s co-authors include Nathanael Lapidus, MD, PhD, Maryvonne Hourmant MD, PhD, Carole Ayav MD, Francois Glowacki MD, PhD, and Cécile Couchoud MD.

Dr. Hsu’s co-authors include Daniel E. Weiner, MD, MS, Harold J. Manley, PharmD, Gideon N. Aweh, MS, Vladimir Ladik, MS, Jill Frament, PharmD, Dana Miskulin, MD, MS, Christos Argyropoulos, MD, Kenneth Abreo, MD, Andrew Chin, MD, Reginald Gladish, MD, Loay Salman, MD, Doug Johnson, MD, and Eduardo K. Lacson, MD, MPH.

Disclosures from Dr. El Karoui: The authors reported no financial disclosures.
Disclosures from Dr. Hsu: This report was supported by Dialysis Clinic, Inc. Dr. Hsu receives support from ASN KidneyCure’s Ben J. Lipps Research fellowship. Mr. Aweh, Dr. Manley, Mr. Ladik, Ms. Frament, Dr. Johnson and Dr. Lacson Jr are all employees of Dialysis Clinic Inc., where Dr. Johnson is Vice Chair of the Board. Dr. Weiner, Dr. Miskulin, Dr. Argyropoulos, Dr. Abreo, Dr. Chin, Dr. Gladish, and Dr. Salman receive salary support to their institution from Dialysis Clinic Inc.


The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

About ASN
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram.

# # #